IO Biotech to Present at Morgan Stanley and H.C. Wainwright Investor Conferences.

IO Biotech's senior management team will provide a corporate update and participate in one-on-one meetings at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference. Members of the team, including Mai-Britt Zocca, Amy Sullivan, and Qasim Ahmad, will present and meet with investors. The webcast replay will be available on the company's website.

IO Biotech (NASDAQ: IOBT), a clinical-stage biopharmaceutical company focused on developing immune-modulatory cancer vaccines, has announced its participation in two upcoming investor conferences in New York. The company will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 7:45 am ET, featuring a fireside chat with CEO Mai-Britt Zocca, CFO Amy Sullivan, and CMO Qasim Ahmad. Additionally, CEO Mai-Britt Zocca will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 8:00 am ET. Webcasts of both presentations will be available in the Investors section of IO Biotech's website for 90 days following the events [1].

The Morgan Stanley conference will feature a fireside chat with Mai-Britt Zocca, Amy Sullivan, and Qasim Ahmad, providing investors with the opportunity to gain insights into the company's strategic direction and ongoing clinical trials. The H.C. Wainwright conference will include a presentation by Mai-Britt Zocca, focusing on the company's progress and future prospects. Both events offer valuable opportunities for investors to engage directly with the senior management team and learn more about IO Biotech's pipeline and clinical developments [2].

IO Biotech's lead cancer vaccine candidate, Cylembio®, is currently in pivotal Phase 3 trials, with topline results expected in the third quarter of 2025. The company is also conducting Phase 2 basket trials investigating Cylembio in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for various solid tumors. These trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to Cylembio [1].

These upcoming conferences come at a critical time for IO Biotech, as the company continues to advance its pipeline and prepare for potential regulatory submissions and market launches. Investors are encouraged to attend these events or tune in to the webcasts for a comprehensive update on the company's progress and future plans.

References:
[1] https://www.stocktitan.net/news/IOBT/io-biotech-announces-participation-in-upcoming-investor-8m2msv58fjrl.html
[2] https://www.globenewswire.com/news-release/2025/09/04/3144481/0/en/IO-Biotech-Announces-Participation-in-Upcoming-Investor-Conferences.html